Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of MK-0616 on Alendronate PK
NCT06772792Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2024
- Primary completion
- Jun 2024
- Modality
- Small Molecules, Cyclic Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of enlicitide in hypercholesterolemia (2 arms), sponsored by Merck & Co. Primary endpoints: Area Under the Concentration-Time Curve from Time 0 to Last of Alendronate, Area Under the Concentration-Time Curve from Time 0 to Infinity of Alendronate and 5 more. Started Apr 2024; status: completed.
02
Drugs
enlicitide
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT06772792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06772792.